article thumbnail

The Benefits of Coronary CTA in Pharmaceutical Clinical Trials

Imaging Technology

Coronary computed tomography angiography (CCTA) is cheaper, easier to use and its results are easier to understand than Intravascular ultrasound (IVUS), making it ideal for clinical trials of cardi

article thumbnail

RefleXion Acquires Global Rights to Radiopharmaceutical Molecule from 3B Pharmaceuticals to Treat High Unmet Need Cancers

Imaging Technology

We are excited, in collaboration with 3BP and others, to advance this molecule through clinical testing to commercialization.” milla1cf Wed, 09/20/2023 - 09:56 September 20, 2023 — RefleXion Medical , Inc., Our partnership with 3BP is as unprecedented in the external-beam radiotherapy industry as our SCINTIX therapy is for cancer treatment.

article thumbnail

First Participant Treated Using NorthStar Medical Radioisotopes’ Electron Accelerator-produced Copper-67 (Cu-67) in Clarity Pharmaceuticals’ Phase I/IIa Theranostic Clinical Trial Investigating Cu-67 SARTATE for Treatment of Neuroblastoma

Imaging Technology

Administration of the therapeutic dose took place as part of an ongoing Phase I/IIa theranostic clinical trial conducted by Clarity Pharmaceuticals to investigate the safety and efficacy of Cu-67 SARTATE in pediatric patients with high-risk neuroblastoma.

article thumbnail

GE HealthCare and MediView Announce the World's First Installation and Clinical Use of Augmented Reality Interventional Suite that Aims to Transform the Practice of Interventional Radiology

Imaging Technology

milla1cf Fri, 06/21/2024 - 20:24 June 21, 2024 — GE HealthCare , a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, and MediView XR Inc., Proceduralists must refer to standard of care imaging and prioritize clinical experience and/or judgment when using the OmnifyXR system.

article thumbnail

TeleDaaS Launches as Premier Provider of Dosimetry as a Service for Clinical Research Organizations

Imaging Technology

TeleDaaS specializes in delivering clinical-grade, precision-based dosimetry analysis and treatment plans to clinical research organizations (CROs) and pharmaceutical manufacturers. The life expectancy of patients on the personalized dosimetry arm of the trial increased to 26.6 months from 10.7

Clinic 54
article thumbnail

First patient treated in NorthStar/Clarity clinical trial

AuntMinnie

Read more on AuntMinnie.com Related Reading: Clarity advances dose escalation for cohort in SECuRE trial Clarity reaches 50% recruitment for SABRE trial NorthStar and Bayer reach Ac-225 supply deal NorthStar manufactures Cu-67 for Clarity Pharmaceuticals NorthStar appoints new president/CEO

article thumbnail

Lantheus appoints new CMO, CSO

AuntMinnie

He will oversee Lantheus’ research and development organization, including research and pharmaceutical development, regulatory affairs, clinical development, medical affairs, and isotope strategy. He has spent more than two decades working for pharmaceutical companies such as Bayer, Bristol-Myers Squibb, Kyowa Kirin, and Pfizer.